Health Care Distributors(IN40221.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Health Care Distributors
IN40221.SH
News
View More

Huadong Medicine Gets U.S. Regulatory Nod for Liver Disease Drug Trial

Huadong Medicine Gets U.S. Regulatory Nod for Liver Disease Drug Trial

marketscreener·
SZ
000963
-0.54%
marketscreener·
SZ
000963
-0.54%

In the "Pharmaceutical Spring Festival Gala" in the United States, Chinese pharmaceutical companies have transformed from "optional consumption" to "essential consumption."

JP Morgan's report indicates that innovative drugs from China have evolved from a "optional configuration" to a category of sources that multinational pharmaceutical companies must systematically evaluate during the asset screening phase. In certain oncology, autoimmune, and metabolic indications, some Chinese pharmaceutical companies' projects have already entered the forefront of global competition for the same targets. This leadership is not reflected in the innovation of mechanisms themselves, but more in clinical execution efficiency, patient enrollment speed, and the pace of indication advancement

Wallstreetcn·
SH
600056
-0.47%
Wallstreetcn·
SH
600056
-0.47%

Huadong Medicine's Hypertriglyceridemia Drug Gains Breakthrough Status in China

Huadong Medicine's Hypertriglyceridemia Drug Gains Breakthrough Status in China

marketscreener·
SZ
000963
-0.54%
marketscreener·
SZ
000963
-0.54%

BAIYUNSHAN PH plans to develop an advanced manufacturing center in Hong Kong

The Investment Promotion Agency held a Traditional Chinese Medicine Development Forum yesterday (8th), gathering over 150 industry stakeholders to discuss topics such as the transformation of TCM research, clinical practice, and standard setting. Chen Zhizhao, General Manager of Guangzhou Pharmaceutical Baiyunshan Hong Kong Co., Ltd., stated at the event that the group is currently engaged in production and manufacturing in Macau, using Macau as a base to develop trade business targeting Portuguese-speaking countries and the Latin American market. He also revealed plans to develop an advanced manufacturing center project in Hong Kong to expand into the UK and US markets

AASTOCKS·
SH
600332
+0.28%
HK
00874
0.00%
AASTOCKS·
SH
600332
+0.28%
HK
00874
0.00%

Jointown Subsidiary Gets China Approval for Anesthetic

Jointown Subsidiary Gets China Approval for Anesthetic

marketscreener·
SH
600998
+0.37%
marketscreener·
SH
600998
+0.37%
© 2026 Longbridge｜Disclaimer